ASX Announcement **5 November 2026**

2026 Annual General Meeting – Chairman's Address to Shareholders

In accordance with ASX Listing Rule 3.13.3, Atomo Diagnostics Limited (**Atomo)** attaches the Chairman's Address to be delivered at Atomo's 2026 Annual General Meeting.

For more information, please contact

Cheri Walker, PhD
Atomo Diagnostics
cheri.walker@atomodiagnostics.com
Phone: +61 2 9099 4750

For Media questions, please contact:

George Hazim
Director
Media and Public Affairs Australia
georgehazim@mediaaffairs.com.au
Phone: +61 417 516 262

This announcement was authorised by the Managing Director & CEO on behalf of the Board

Chairman's Address to Shareholders — Atomo Diagnostics Limited (ASX: AT1)

5th November 2026

Good morning, everyone, and welcome to Atomo Diagnostics' Annual General Meeting. On behalf of the Board, I thank you for joining us today and for your continued support of the Company.

The past year has been a transitional year for Atomo. Whilst navigating a volatile operating environment across the global diagnostics sector, we have continued to execute our strategy of delivering innovative, user-centred rapid testing solutions that improve access to accurate and reliable diagnostics worldwide.

Atomo is starting to fulfil on the promise from its current proprietary HIV franchise and through OEM partnerships, posting significant year-on-year growth of more than 40%. As the company prepares for future global endeavours, Atomo transitioned its Chief Executive role to Dr. Cheri Walker, to focus on commercial sales, partnerships and the new product pipeline. We thank John Kelly, the founding CEO for his long service that has brought Atomo to this exciting juncture.

Our focus remains on the patient, providing blood-based testing products that bring increased usability and performance to the patient setting, in both professional use and the self-test setting.

The shift to decentralised, at-point-of-care and self-testing solutions remains a strong and growing trend. Government policy and regulators are continuing to see the benefits of point-of-care and self-testing. As new and better tests remove the need for confirmation testing, treatment decisions can be made more rapidly in locations where there is little access to centralised testing or the time for that testing could delay life-saving care.

Atomo's core purpose remains clear — to simplify and democratise diagnostic testing through our patented device technology. Our products are designed to make testing easier, safer, and more reliable, whether used by healthcare professionals or self-test users in the home.

Over the past year, we have:

- Advanced Atomo's Active Syphilis product and added ALT liver and Gen 4 HIV to our proprietary product pipeline;
- Completed development projects with two OEM providers for Ferritin and Brain Disease/Stroke indications;
- Continued to grow our HIV franchise by more than 40% through international, public health and pharmacy sales;
- Made strategic moves to commission a second blister machine in Sydney and started developing new tooling to add more flexibility plus began the development of higher cavitation moulding meant to improve gross margins; and
- Streamlined our operating model to enhance efficiency and preserve capital.

Atomo HIV franchise continues to grow and perform well, providing solid growth of 21% in FY26. Atomo's technology is proven, being the first HIV/AIDS self-test to be approved by the Australian Therapeutic Goods Administration (TGA). We continue to drive growth in international markets, pharmacies, and public health applications across ANZ.

Our OEM franchise is starting to drive accelerated growth for Atomo, posting more than 200% year-on-year growth. Atomo is the exclusive licensor, manufacturer and supplier of the Pascal cassette to Lumos (ASX:LDX) for its FebriDx® product. Using Atomo's Pascal cassette, FebriDx® has previously secured 510k clearance from the US FDA and received CLIA waiver from the US FDA. The CLIA waiver trial showed that Pascal has enabled greater than 99% concordance between trained and untrained operators using FebriDx®.

The Board remains confident that the Company's technology platform, intellectual property, and strong global relationships position Atomo well to participate in the continuing evolution of decentralised diagnostics.

During the year we undertook a successful capital raising, supporting working capital and enabling us to reshape our organisation and position ourselves for the next growth phase. We want to thank existing and new shareholders for their support.

In parallel, management has taken decisive steps to reduce costs and strengthen our balance sheet. This financial discipline will support our ability to pursue commercial opportunities in a sustainable manner while continuing to invest selectively in innovation.

Looking forward, Atomo's strategy is centred on several priorities including:

1. Expanding Atomo's own proprietary test pipeline (as exampled by active syphilis, ALT Liver and recently announced HIV Gen 4);
2. Leveraging our proven platform and identifying new OEM partnerships in testing applications where usability and accuracy are critical; and
3. Maintaining operational excellence, focus on improving operating scale and gross margins, and prudent capital management as we build towards profitability.

I would like to take this opportunity to thank my fellow Director, Mr Tony May, for his support and guidance. Also, our CEO/MD, Dr Cheri Walker, and the entire Atomo team for their dedication and professionalism throughout the year. Their efforts have ensured that Atomo continues to be recognised as a leader in user-centric diagnostic design and manufacturing.

I would also like to acknowledge the ongoing support of our shareholders. Your confidence in our vision enables us to continue driving innovation in an industry that plays such a vital role in global public health.

The Board remains committed to delivering long-term value through disciplined execution, strategic partnerships, and continued focus on innovation and quality.

Thank you once again for your attendance and support. I will now hand over to our CEO/MD, Dr Cheri Walker, to provide further detail on the Company's operational and commercial progress during the year.